GBS6

**GBS6** is Pfizer's investigational hexavalent maternal vaccine for prevention of invasive disease caused by *Streptococcus agalactiae* in newborns and young infants. Also designated **PF-06760805**, it comprises capsular polysaccharide antigens from six Group B Streptococcus serotypes conjugated to the carrier protein CRM197. Maternal intramuscular vaccination is intended to generate serotype-specific maternal antibodies that are transferred transplacentally to the infant, providing passive protection during early life. GBS6 received FDA Fast Track designation in 2017 and Breakthrough Therapy designation in 2022; Pfizer's Phase 3 BEATRIX study is evaluating the vaccine in healthy pregnant participants and their infants. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b))

Other names

Group B Streptococcus 6-Valent Polysaccharide Conjugate VaccineHexavalent Group B Streptococcus Capsular Polysaccharide Conjugate Vaccine